Vaqta

Vaqta is a vaccine used to prevent Hepatitis A, a liver disease caused by the Hepatitis A virus (HAV). It is produced by Merck & Co., an American multinational pharmaceutical company. Vaqta is administered through injection and is recommended for individuals aged one year and older.

Composition[edit | edit source]

Vaqta is composed of inactivated or killed Hepatitis A virus to stimulate the body's immune response without causing the disease. The virus is propagated in MRC-5 human diploid cells. The vaccine also contains aluminum hydroxide as an adjuvant to enhance the immune response, and sodium borate as a pH stabilizer.

Usage[edit | edit source]

Vaqta is used to immunize individuals against Hepatitis A. It is particularly recommended for those at high risk of infection or complications from Hepatitis A, including travelers to areas with high rates of Hepatitis A, men who have sex with men, users of recreational drugs, people with chronic liver disease, and individuals working with nonhuman primates.

Administration[edit | edit source]

Vaqta is administered in two doses, with the second dose given six to 18 months after the first. The vaccine is injected into the muscle of the upper arm for adults and into the thigh muscle for children.

Efficacy[edit | edit source]

Studies have shown that Vaqta is highly effective in preventing Hepatitis A. The vaccine provides immunity against Hepatitis A for at least 20 years in adults and at least 14 to 20 years in children.

Side Effects[edit | edit source]

Common side effects of Vaqta include pain at the injection site, headache, and loss of appetite. Serious side effects are rare but can include severe allergic reactions.